arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Theravance Biopharma, Inc.

TBPH
$17.04 0.00 (0.00%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
56 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
85
Health
Excellent
Bullish
auto_awesome

Analytical Summary

Theravance Biopharma, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $880.4M
Dividend Yield —
Revenue Growth -20.9% ↘
Op. Margin -39.9% ↗
ROIC -3.5% ↘
FCF / Share $-0.13 ↘
Trailing P/E —
Price / Book 3.1x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

56-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$20.73M
↓ -20.9% —
Net Income Profit after all expenses
$-5.90M
↓ -19.6% —
Operating Margin Operating profit as % of sales
-39.9%
↑ +25.5% 22th
FCF / Share Free cash flow per share
$-0.13
↓ -109.4% —
Long-Term Debt Long-term obligations
$624.70M
↑ +0.5% —
trending_up

Bullish Indicators

  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
74
Returns ↓
95
Cash Quality ↑
88

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 15 years · 56 quarters